Evgen Pharma PLC - Liverpool-based clinical stage drug development company - Says that after a review of the first 60 patients enrolled, the Data Safety Monitoring Committee for the STAR Covid-19 trial has concluded that there are no concerns regarding patient safety or data quality that would prevent continuation of the trial. Says the next event in the trial involves an assessment of safety and futility by the DMC of unblinded data on the first 100 patients treated. In addition to the DMC safety and futility assessment, Dundee University has decided to review the top-level unblinded data in a preliminary assessment of possible efficacy, it adds.
Chief Executive Officer Huw Jones says: '"We are pleased with the conclusion of the data monitoring committee with regard to safety and data quality in the STAR COVID 19 study. The former conclusion reinforces what we know about the positive safety and tolerability of SFX-01 from previous studies and the latter is yet another testament to the excellent work carried out by Professor James Chalmers and his colleagues at Dundee under challenging circumstances."
Current stock price: 7.95 pence
Year-to-date change: down 22%
By Arvind Bhunjun; arvindbhunjun@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
